Mirte Muller, Myron G Best, Vincent van der Noort, T Jeroen N Hiltermann, Anna-Larissa N Niemeijer, Edward Post, Nik Sol, Sjors G J G In 't Veld, Tineke Nogarede, Lisanne Visser, Robert D Schouten, Daan van den Broek, Karlijn Hummelink, Kim Monkhorst, Adrianus J de Langen, Ed Schuuring, Egbert F Smit, Harry J M Groen, Thomas Wurdinger, Michel M van den Heuvel
BACKGROUND: Anti-PD-(L)1 immunotherapy has emerged as a promising treatment approach for non-small cell lung cancer (NSCLC), though the response rates remain low. Pre-treatment response prediction may improve patient allocation for immunotherapy. Blood platelets act as active immune-like cells, thereby constraining T-cell activity, propagating cancer metastasis, and adjusting their spliced mRNA content. OBJECTIVE: We investigated whether platelet RNA profiles before start of nivolumab anti-PD1 immunotherapy may predict treatment responses...
May 26, 2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine